TQB0 Stock Chart & Stats
€1.12
-€0.07(-5.88%)
At close: 4:00 PM EDT
€1.12
-€0.07(-5.88%)
Day’s Range― - ―
52-Week Range€0.84 - €2.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€62.81M
Enterprise Value€57.43M
Total Cash (Recent Filing)€7.63M
Total Debt (Recent Filing)€3.49M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Dec 10, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding47,111,668
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)6.39
Price to Sales (P/S)4.89
P/FCF Ratio-5.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.86Price Target Upside245.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€16.23M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Margin ExpansionConsecutive year-over-year growth combined with higher gross margin indicates improving commercial traction and better economics per dollar of revenue. If sustained, this combination can provide greater operating leverage and support investment in the company’s platform transition over the next several quarters.
Pharma Relationships And Clinical ValidationDeep relationships with leading pharmaceutical companies and a record of programs reaching clinical trials support credibility in a regulated, technically demanding market. This customer access and demonstrated scientific relevance can improve the company’s ability to win platform partnerships and expand existing engagements.
Platform-based Business ModelMoving from discrete fee-for-service work toward platform partnerships may increase participation in the economics of assets created with customers. Over time, this model could improve revenue durability, deepen client integration, and create more scalable value across multiple discovery programs and workflows.
Bears Say
Severe Losses And Cash BurnPersistent operating losses are translating into substantial cash outflows rather than remaining primarily non-cash accounting charges. Continued burn can consume available liquidity, increase reliance on external financing, and restrict the company’s ability to fund ReefIQ, internal pipeline work, and commercial expansion independently.
Material Equity ErosionThe sharp reduction in the capital base reflects the cumulative effect of sustained losses and leaves less balance-sheet capacity to absorb execution setbacks. If losses continue, further erosion could weaken financial resilience and make future funding or strategic investment more consequential for existing stakeholders.
Uncertain ReefIQ MonetizationThe strategic shift toward recurring platform revenue has not yet produced predictable contract timing or revenue visibility. Milestone-based early work and extended customer reviews can delay conversion of the funnel into annual recurring revenue, making near-term scaling dependent on adoption and execution.
MindWalk Holdings News
TQB0 FAQ
What was MindWalk Holdings’s price range in the past 12 months?
MindWalk Holdings lowest stock price was €0.84 and its highest was €2.80 in the past 12 months.
What is MindWalk Holdings’s market cap?
MindWalk Holdings’s market cap is €62.81M.
When is MindWalk Holdings’s upcoming earnings report date?
MindWalk Holdings’s upcoming earnings report date is Dec 10, 2026 which is in 59 days.
How were MindWalk Holdings’s earnings last quarter?
MindWalk Holdings released its earnings results on Sep 14, 2026. The company reported -€0.081 earnings per share for the quarter, missing the consensus estimate of -€0.048 by -€0.033.
Is MindWalk Holdings overvalued?
According to Wall Street analysts MindWalk Holdings’s price is currently Undervalued.
Does MindWalk Holdings pay dividends?
MindWalk Holdings does not currently pay dividends.
What is MindWalk Holdings’s EPS estimate?
MindWalk Holdings’s EPS estimate is -0.06.
How many shares outstanding does MindWalk Holdings have?
MindWalk Holdings has 47,111,668 shares outstanding.
What happened to MindWalk Holdings’s price movement after its last earnings report?
MindWalk Holdings reported an EPS of -€0.081 in its last earnings report, missing expectations of -€0.048. Following the earnings report the stock price went down -14.091%.
Which hedge fund is a major shareholder of MindWalk Holdings?
Currently, no hedge funds are holding shares in DE:TQB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.86 (245.05% Upside)
€3.86 (245.05% Upside)
Blogger Sentiment
Neutral
DE:TQB0 Sentiment 50%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.11%
12-Months-Change
Fundamentals
Return on Equity
-144.31%
Trailing 12-Months
Asset Growth
-58.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MindWalk Holdings
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
TQB0 Company Deck
TQB0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive, supported by 21% year-over-year revenue growth, five consecutive quarters of year-over-year growth, gross margin expansion to 59%, progress launching ReefIQ, a strong pharmaceutical customer base, clinical validation, platform partnership traction, and a USD 30 million non-dilutive financing commitment. The main negative factors were the increased $6.1 million loss, higher operating expenses, a lower cash balance, uncertain and potentially lumpy timing for ReefIQ revenue, and the absence of announced enterprise contracts or specific closing timelines.View all DE:TQB0 earnings summariesTQB0 Stock 12 Month Forecast
Average Price Target
€3.86
▲(245.05% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―